ArticleCritical care (London, England)2021
Burden of pneumococcal pneumonia requiring ICU admission in France: 1-year prognosis, resources use, and costs.
Article in Critical care (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Management cost of acute respiratory infections in older adults in China: A systematic review and meta-analysis.Journal of global health · 2024Pooled it
- Costs of management of acute respiratory infections in older adults: A systematic review and meta-analysis.Journal of global health · 2022Pooled it
- Changing Epidemiology of Severe Pneumococcal Pneumonia in Adults at a Tertiary Hospital between 2010 and 2024.Tuberculosis and respiratory diseases · 2026Article
- AI-Assisted Systematic Literature Review of the Economic Burden of Pneumococcal Disease: Development and Validation Study.JMIR AI · 2026Article
- Estimating the economic burden of lower respiratory infections in China from 2020 to 2040: a health-augmented macroeconomic modelling study.The Lancet regional health. Western Pacific · 2026Article
- Metagenomics reveals pathogenic diversity and temporal dynamics in severe pneumonia among patients in adult intensive care unit.BMC infectious diseases · 2026Article
- Factors associated with severe pneumonia in adults hospitalised with community-acquired pneumonia in Mongolia.BMC public health · 2026Article
- Determinants of pneumonia among adult asthmatic patients attending public hospitals in Awi Zone, Northwest Ethiopia: A case control study.SAGE open medicine · 2026Article
- Clinical burden of pneumococcal disease among adults in France: A retrospective cohort study.Human vaccines & immunotherapeutics · 2025Article
- Epidemiology of severe acute respiratory infections in South Korea: a nationwide surveillance study.BMC pulmonary medicine · 2025Article
- Prediction of mortality risk in patients with severe community-acquired pneumonia in the intensive care unit using machine learning.Scientific reports · 2025Article
- Hospital Burden of All-Cause Pneumonia and Nonbacteremic Pneumococcal Pneumonia in Adults in France Between 2013 and 2019.Open forum infectious diseases · 2024Article
- Community-acquired Klebsiella pneumoniae pneumonia in ICU: a multicenter retrospective study.Annals of intensive care · 2024Article
- Diabetes Mellitus and Pneumococcal Pneumonia.Diagnostics (Basel, Switzerland) · 2024Review
- Meningitis in critically ill patients admitted to intensive care unit for severe community-acquired pneumococcal pneumonia.Annals of intensive care · 2023Article
- Article
- Impact of establishing a respiratory high dependency unit for SCAP patients on the therapeutic effect, prognosis, and expenditure: a retrospective case-control study.Scientific reports · 2022Article
- Severe community-acquired pneumonia in Reunion Island: Epidemiological, clinical, and microbiological characteristics, 2016-2018.PloS one · 2022Article
- Cortisol in Peripheral Blood Predicts the Severity and Prognosis in Patients with Liver Failure at 90 Days.Risk management and healthcare policy · 2021Article
- Survival at 3, 6 and 12 months in patients diagnosed with community-acquired pneumonia in Colombia: a retrospective cohort study.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious DiseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCommunity-acquired pneumonia (CAP), especially pneumococcal CAP (P-CAP), is associated with a heavy burden of illness as evidenced by high rates of intensive care unit (ICU) admission, mortality, and costs. Although well-defined acutely, determinants influencing long-term burden are less known. This study assessed determinants of 28-day and 1-year mortality and costs among P-CAP patients admitted in ICUs.
methodsData regarding all hospital and ICU stays in France in 2014 were extracted from the French healthcare administrative database. All patients admitted in the ICU with a pneumonia diagnosis were included, except those hospitalized for pneumonia within the previous 3 months. The pneumococcal etiology and comorbidities were captured. All hospital stays were included in the cost analysis. Comorbidities and other factors effect on the 28-day and 1-year mortality were assessed using a Cox regression model. Factors associated with increased costs were identified using log-linear regression models.
resultsAmong 182,858 patients hospitalized for CAP in France for 1 year, 10,587 (5.8%) had a P-CAP, among whom 1665 (15.7%) required ICU admission. The in-hospital mortality reached 22.8% at day 28 and 32.3% at 1 year. The mortality risk increased with age > 54 years, malignancies (hazard ratio (HR) 1.54, 95% CI [1.23-1.94], p = 0.0002), liver diseases (HR 2.08, 95% CI [1.61-2.69], p < 0.0001), and the illness severity at ICU admission. Compared with non-ICU-admitted patients, ICU survivors remained at higher risk of 1-year mortality. Within the following year, 38.2% (516/1350) of the 28-day survivors required at least another hospital stay, mostly for respiratory diseases. The mean cost of the initial stay was €19,008 for all patients and €11,637 for subsequent hospital stays within 1 year. One-year costs were influenced by age (lower in patients > 75 years old, p = 0.008), chronic cardiac (+ 11% [0.02-0.19], p = 0.019), and respiratory diseases (+ 11% [0.03-0.18], p = 0.006).
conclusionsP-CAP in ICU-admitted patients was associated with a heavy burden of mortality and costs at one year. Older age was associated with both early and 1-year increased mortality. Malignant and chronic liver diseases were associated with increased mortality, whereas chronic cardiac failure and chronic respiratory disease with increased costs.
trial registrationN/A (study on existing database).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.